AU9389098A

AU9389098A - Modulation of immune responses

Info

Publication number: AU9389098A
Application number: AU93890/98A
Authority: AU
Inventors: Derrick Cecil Attfield; Gabriel Johannes Du Preez; Carl John Landauer; Volker Reinhard Schillack; Johannes Beyers Van Den Bogaerde
Original assignee: Namibia Medical Investments Pty Ltd
Current assignee: Namibia Medical Investments Pty Ltd
Priority date: 1997-09-16
Filing date: 1998-09-16
Publication date: 1999-04-05
Anticipated expiration: 2018-09-16
Also published as: CA2304119A1; AU737867B2; EP1019063A4; JP2001516721A; CN1279612A; NZ503418A; NO20001341L; NO20001341D0; EP1019063A1; BR9812321A; IL135091A0; WO1999013885A1

Description

WO 99/13885 PCT/US98/19126 MODULATION OF IMMUNE RESPONSES FIELD OF THE INVENTION THIS invention relates to the treatment of conditions in the human body which are associated with inappropriate immune responses. More 5 particularly, this invention is concerned with the treatment of conditions in which the inappropriate immune response is associated with inappropriate immune cell metabolic activity which, in turn, is mediated, or at least thought to be associated with the Tyrosine Kinase Cascade in which Protein Tyrosine Kinase, hereinafter referred to as "PTK", plays an important role, 10 or with Cycline Dependent Kinase, hereinafter referred to as "CDK" in the immune cell. The invention consequently provides for the treatment of and for medicaments for use in the treatment of, a large variety of ailments associated with inappropriate immune responses in the animal body, which term is intended herein to include the human body. 15 BACKGROUND TO THE INVENTION It is well known that immune cells play an important role in the immune system of the animal body. A variety of such cells have been identified. Amongst these the T lymphocytes, also known as T-cells, and the B lymphocytes, also known as B-cells, have been recognized for their C sCTT -1 I C T 1I 9 al IDCT'lITI T :I..IIFFT IIRI II I=9F WO 99/13885 PCT/US98/19126 important role in the immune response of the animal body against foreign infections. Additionally, other cells capable of producing immunological mediators have an immune function. The normal, or appropriate response of such cells to an extraneous stimulant, for example a viral or bacterial 5 infection of the animal body or to endogenous immune stimulants, for example oncogenic transformation, is to cause the activation of the metabolic pathways of the cells in issue resulting in the production of immunological mediators including cytokines, lymphokines, chemokines, growth factors and cytotoxic cells and usually also gives rise to the 10 proliferation of such immune cells. The immunological mediators, in turn, perform or complement the function of neutralizing the infective agent, or toxins released by it, as part of the natural infection combating or healing process of the body. These pathways involve complex biochemical and signalling systems to which further reference is made below. 15 It is also well-known that, for reasons which are not fully understood at present, the response of the immune system is sometimes abnormal and gives rise to the expression by, and secretion from, the immune cells of products considered to be inappropriate. While such abnormality may be associated with an abnormal proliferation of such cells, it is not necessarily 20 the case. Such abnormality in immune cell activity may simply be manifested by the secretion of an inappropriate quantity of immune cell products without necessarily being associated with an increase in the c irr r 1-2- I I 9 as IDCTITIITE CLJCET IRI II ?" 9R1 WO 99/13885 PCT/US98/19126 proliferative activity of such cells. Inappropriate immune response has been implicated in a large variety of ailments affecting the human and animal body. The present invention is directed at the treatment of such conditions as will appear below. In the 5 conditions in question the manifestation of an inappropriate immune response, including the presence of cytotoxic cells, and/or of an inappropriate quantity of the immune cell products required to combat a particular infection or condition, give rise to what may be thought of as an attack by the immune system on specific organs of the body itself, or even 10 to a non-specific immunological attack on the body generally, rather than such attack being appropriately directed at the extraneous or endogenous antigen or agent or metabolites such as toxins produced thereby. The target organs of such inappropriate attack are diverse and, as will be seen from the list of conditions enunciated below, encompass the skin, the muscles, the 15 skeletal structure, the joints, the blood, the brain and nervous system, the internal organs including the bowel, kidneys, lungs, liver, and even the sensory organs including the eyes. In some of the conditions or syndromes with which this invention is concerned a primary or initiating causative agent or stimulant for the 20 immune response has been identified. It is however a feature of such conditions or syndromes that the immune response may persist even after -3 IlIRRTITIITF RHWFT (RULE 261 WO 99/13885 PCT/US98/19126 the causative agent or stimulant, such as, for example, a viral or microbial infection or other form of antigen, has been eliminated by the body's own defense mechanism, namely the immune system, or by means of pharmaceutical intervention, or by a combination thereof. In other cases 5 no, or at least no as yet identified causative agents are known. All these conditions are considered to be immune mediated ailments. For a clear understanding of the nature and impact of the present invention it is necessary briefly to explain the current understanding of the nature of immune response activity in the body. Immune cells, and in particular T 10 lymphocytes are dependent for their biological function on signal transduction through the T cell receptor which is unique to, and present only on T lymphocyte surfaces. The T cell receptor is a complex group of surface molecules including CD 4 or CD 8 surface molecules. The CD 4 , CD 8 and certain other surface molecules are capable of transmitting a signal from 15 the external surface of the cell membrane to the internal environment of the cell i.e. to the cytoplasma of the cell. These signals are transmitted through an enzyme pathway known as the Tyrosine Kinase Cascade. Activated Tyrosine Kinases phosphorilate certain proteins leading to the development of new signal intermediates. In this cascade the enzyme known as Protein 20 Tyrosine Kinase [PTK] plays an important role. This enzyme is a protein featuring free sulfhydryl groups. The Tyrosine Kinase cascade ultimately terminates in the expression of specific genes in the T cell. These genes -4 Q1IR.TITIITF RMFT (RULE 261 WO 99/13885 PCT/US98/19126 respectively code for a variety of immunological mediators including cytokines and for structural proteins required for cell proliferation. The immune response mediated ailments with which this invention is concerned are, as mentioned before, associated with uncontrolled expression of 5 immunological mediators by the immune cells and uncontrolled cytotoxic cell activity. DISCUSSION OF PRIOR ART Dimethylformamide or DMF is a volatile, non-ionic liquid at room temperature and is well known for its use as an industrial solvent. It is 10 used, amongst others, in the manufacturing process of various products for human consumption, including in the manufacturing processes of pharmaceutical products. Its toxicity is well studied. It is known to be non toxic at levels many times higher than the levels with which the present invention is concerned. Such toxicity as DMF has at high levels of 15 concentration in the human body is attributed to its depletion of glutathione in hepatocytes in the liver resulting in hepatocyte necrosis. It has been claimed by Cryopreservation Technologies CC in PCT application PCT/US96/19697 published on 26 June 1997 under WO 97/22248 that dimethylformamide and related compounds may be used in 20 the treatment of viral and/or microbial infections. That publication cites -5 CI IRTITI IT= QWI=I=T IRULE 261 WO 99/13885 PCT/US98/19126 examples showing that DMF may be administered transdermally to a patient to obtain a DMF in blood level aimed to be 100 ppm, but the levels reported as actually achieved varied from this target, in HIV positive patients. It further reports that after such treatment with DMF for a period 5 of less than three weeks, the viral load in the patient had dropped from 120 000 to 500/ml. It also reports an improvement in the symptoms of acne and German measles in patients treated with DMF to achieve a DMF/blood level of 50 - 100 ppm. That disclosure relates to the use of DMF as an anti viral and anti-microbial agent and is silent on the immune response 10 regulatory properties of the compounds with which this invention is concerned, and on the use of such compounds in the treatment of immune cell related illnesses or the use of such compounds in the manufacture of medicaments for use in the treatment of such conditions. OBJECT OF THE INVENTION 15 It is an object of the invention to provide a method of modulating an immune response in the animal or human body and of treating ailments associated with inappropriate immune responses in the animal, including human, body. -6 q1lRqTITIITF RHIFT (RULE 261 WO 99/13885 PCT/US98/19126 DESCRIPTION OF THE INVENTION It has now surprisingly been found, in contradistinction with the prior art knowledge regarding the toxicity and anti-viral and anti-bacterial properties of DMF that such product may be used in sub-toxic dosages to modulate the 5 immune responsive metabolic processes in cells having an immunological function by affecting such processes to stimulate or suppress the expression or secretion of immunological mediators by such cells without destruction of the cells through the administration of DMF to the body. According to the present invention there is thus provided a method of 10 affecting an immune response in an animal comprising the steps of administering to such animal a non-toxic immune modulating effective quantity of a compound selected from the group consisting of compounds of the general chemical formula (I)

R,-CO-NRR

3 (I) 15 wherein

R

1 is selected from the group consisting of H and lower [i.e. C to C 3 ] alkyl and C 2 to C 3 alkenyl groups;

R

2 and R3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl 20 groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH 2

)

n - group 1RTITIIT -7-T RLE 261 liRTITIlTF RMMEFT (RULE 263 WO 99/13885 PCT/US98/19126 wherein n is any number from 2 to 5, or the group -(CH 2

)

2

-O-(CH

2

)

2 and metabolites and prodrugs thereof. The immune response to be affected by the above method may be an immune response of the immune cells forming part of the immune system 5 of the body. The immune cells may be T lymphocytes and or B lymphocytes. The method may be performed to reduce the expression or secretion of immune cell products in the body. According to a further aspect of the present invention there is provided a 10 method of treatment of an animal afflicted with an ailment associated with inappropriate immune responses in that animal, comprising the steps of administering to such animal a non-toxic therapeutically effective quantity of a compound selected from the group consisting of compounds of the general chemical formula (I) 15

R,-CO-NR

2

R

3 (I) wherein R, is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkyl and C, to C 3 alkenyl groups;

R

2 and R 3 are the same or different and each is selected from the -8 C1 IRTITI ITI" RM I4IT (RILI 261 WO 99/13885 PCT/US98/19126 group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH) n - group wherein n is any number from 2 to 5, or the group -(CH,) 2

-O-(CH

2

)

2 5 and metabolites and prodrugs thereof. According to another aspect of the invention it relates to use of a compound selected from the group consisting of compounds of the general chemical formula (I)

R

,

-CO-NR

2

R

3 (I) 10 wherein

R

1 is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkvl and C 2 to C 3 alkenyl groups;

R

2 and R 3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl 15 groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH 2

)

n - group wherein n is any number from 2 to 5, or the group -(CH 2

)

2

-O-(CH

2

)

2 and metabolites and prodrugs thereof in the manufacture of a medicament for use in a method of treatment of an 20 animal afflicted with an ailment associated with inappropriate immune responses in that animal. -9 1 IRTITIITI RIWF FT (RULE 261 WO 99/13885 PCT/US98/19126 Further according to the present invention it relates to a pharmaceutical composition comprising a compound selected from the group consisting of compounds of the general chemical formula (I) Rj-CO-NR 2

R

3 (I) 5 wherein

R

1 is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups; R, and R 3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C, to C 3 alkenyl 10 groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH) n - group wherein n is any number from 2 to 5, or the group -(CH 2

)

2

-O-(CH

2

)

2 and metabolites and prodrugs thereof in a pharmaceutically acceptable dosage form for use in the treatment of an 15 animal afflicted with an ailment associated with inappropriate immune responses in that animal. In all the treatment related aspects of the invention the ailment to be treated may be any one of the following: Systemic Lupus Erythematosus [SLE] 20 Scleroderma [Systemic sclerosis] Vasculitis Syndrome [including Wagener's thrombosis and all forms of Giant cell arthritis] - 10 1lRmTITIITF WF4T (RULE 261 WO 99/13885 PCT/US98/19126 Dermatomiositis Asthma Adult Respiratory Distress Syndrome [ARDS] Systemic Inflammatory Response Syndrome [SIRS] 5 Inflammatory Bowel Disease Chronic Hepatitis Rheumatoid Arthritis Rheumatic fever Myasthenia Gravis 10 Multiple Sclerosis Psoriasis Eczema Multiple myeloma Reiter's Syndrome 15 Glomerulonephritis Polymyalgia Rheumatica Ankylosing spondylitis Polyarteritis Nodosa Allergic Rhinitis 20 Diabetes mellitus Optical Neuritis Acute Transversmielitis Head Injuries - 11 CIIRTIT ITI RMI-ilFT (RULE 283 WO 99/13885 PCT/US98/19126 Spinal Cord injuries Post sub-Arachnoidal Bleeding Vasospasma In all the aforementioned aspects of the invention the compounds of choice is dimethylformamide and its metabolites namely N-methylformamide, N 5 methyl-isocyanite and its carbamates, and N-acetyl-S-(N methylcarbamoyl)cysteine and any prodrugs of such metabolites. Further according to the invention the method is performed by administering to the patient to be treated a quantity of DMF sufficient to maintain a DMF-plasma level of between 0.001% and 0.1% and most 10 preferably between 0.01% and 0.05%. Likewise, the medicament according to the invention is adapted in use to administer to the patient a quantity of DMF at such rate as to achieve and maintain a DMF-plasma level of between 0.001 % and 0.1% and most preferably between 0.01% and 0.05%. Also, in all aspects of the invention the compound may be administered by 15 any route of administration, such as orally, nasally, rectally, intravenously, intramuscularly, subcutaneously or transdermally. The preferred route of administration of the compound is transdermally. Preferably, however, it is administered by a transdermal patch. As will appear from the examples below, mixed lymphocytes were exposed - 12 Q1 IRTITIITI= RM-FT (RULE 261 WO 99/13885 PCT/US98/19126 to a non-specific stimulator of lymphocytes, such as PHA at 1 to 10 Ag per 200 AL. When these lymphocytes were concurrently also exposed to very low concentrations of DMF a decreased metabolic activity was demonstrated as evidenced by the fact that these cells were less capable of reducing a 5 patented [U.S. Patent No. 5,501,959] redox indicator. This inhibition of metabolic activity is not the result of direct cell toxicity as is evidenced by the fact that the therapeutic concentration to effect inhibition of metabolic activity and therefor proliferation, is lower than a concentration which causes activation of cell metabolism and therefor proliferation. 10 By bringing the immune active cells in need of modulation into contact with DMF or any of its metabolites in a therapeutic concentration, it is possible to diminish the metabolic activity of cells with immune function. By decreasing the metabolic activity of T lymphocytes the responsiveness of these T lymphocytes to certain T lymphocyte specific antigens and antigen, 15 major histocompatibility complex molecule combinations will be severely inhibited. It is the antigen specific inhibition of T lymphocyte responses that forms the basis of the clinical application of DMF to modulate immune cell mediated diseases proposed by the present invention. For the transdermal administration of DMF to a patient in need of 20 treatment according to the invention it is proposed to use a multi-purpose transdermal administration system that is able to deliver a variety of drugs - 13 qllRRTITUlTF RHIIFT (RULE 26 WO 99/13885 PCT/US98/19126 including DMF and the above-mentioned related compounds therapeutically. The patch design parameters considered important include the following: 1. The patch must have pre-determined dimensions as it determines the 5 amount of active ingredient [drug] absorbed over a certain time. 2. Drug administration must not be time dependent. 3. Drug concentration should be variable according to patient profile. 4. The patch must be stable, and deliver repeatable therapeutic concentrations of agent [drug] that is administered. 10 5. The tempo of drug [agent] administration is determined by the skin, thus the desorption of the drug is through the membrane should be the same or very close to the absorption tempo of the skin. 6. The patch and the drug must have a relative long shelf life. To achieve the above requirements a patch has been designed with the 15 following features: - 14 CI IRCTITI ITrI= QlFT RULF 2R8 WO 99/13885 PCT/US98/19126 1. High density nylon backing material. 2. Safety border consisting of nylon of PATFE [Teflon]. 3. Low density septa NYLON or PTFE. 4. Hydrophilic or hydrophobic NYLON or PTFE membrane 5 [Depending on which drug is administered]. 5. Membrane pore size of 0.05-0.45 micron depending on which drug is administered. 6. Diatomaceous earth [SiO 2 ] adsorbent material. 7. Stabilisation agent [Salting agent to decrease evaporation as well as 10 homogenic weight distribution through the membrane]. 8. Suitable skin adhesive which is not reactive with the drug. 9. Anti-irritation agent - Vitamin E [This agent can be applied before, during or after application of the agent to protect the skin against side effects]. - 15 Q1IRTITI ITS= qMI=T (RULE 261 WO 99/13885 PCT/US98/19126 More particularly a patch was made up as follows: 1. Backing material and septa Description Round semi-transparent nylon disk 0.1-0.4 mm thick Diameter 20 - 100 mm 5 Average mass 100 mg - 600 mg Septa description Round soft polypropylene/polyethylene with nylon or PTFE backing Septa diameter 5 - 25 mm Septa thickness 0.2 - 1 mm 2. Teflon membrane 10 Description Round white membrane Diameter 20 - 100 mm Average Mass 50 - 500 mg Pore Size 0.2 - 0.8 micron 3. Teflon border ring 15 Description Round semi-transparent 0.1 - 0.4 mm thick Inner diameter 10 - 90 mm Outer diameter 20 - 100 mm - 16 QlIRqTITIITP HEET (RULE 261 WO 99/13885 PCT/US98/19126 Average mass 20 - 200 mg 4. Absorbent material Description Silicon dioxide [diatomaceous earth] Mass / patch 1 - 10 g 5 Stabilisation agent Sodium chloride and magnesium / calcium description carbonate APPLICATION TECHNIQUE Indirect administration of the drug such as DMF may be done by introducing a known amount of the active agent with a syringe into the 10 Silicon dioxide adsorbent after the patch had been applied to the skin. The following advantages are obtained by using this technique: 1. Controlled agent administration from an ampoule/container onto a patch. 2. Therapeutic agent dosage can be predetermined according to patient's 15 profile. - 17 QlRTIT IIT - RHET (RULE 261 WO 99/13885 PCT/US98/19126 3. By making the agent concentration dependent, the time of treatment and area of skin exposure stays constant during treatment. 4. Patch and agent can be applied with confidence without overdosing the patient. 5 5. Patch and agent are easy administered and the patient can be discharged after administration. 6. Patch is very stable, has an unlimited shelf life, and agent administered from an ampoule has at least a two year expiry date, unless otherwise stipulated. 10 EXAMPLES OF THE INVENTION The invention will now be demonstrated with reference to the following examples without thereby limiting the scope of the invention to the illustrative embodiments. EXAMPLE 1 15 Peripheral human lymphocytes were isolated from whole blood of healthy volunteers by using a density gradient separation technique well described - 18 1 IRrTITI ITFI= RHI4FT (RULE 261 WO 99/13885 PCT/US98/19126 and known in the immunology research literature. Briefly described, by this technique peripheral whole blood is diluted 1:2 with phosphate buffered saline or cell culture media such as RPMI1640. A density gradient such as Histopaque 1077 [Sigma Cat # 1077] is then layered underneath the diluted 5 peripheral blood, taking care to create a sharp interface. The density gradient is then centrifuged at 600 g for 20 to 25 minutes. After centrifugation a clear buffy coat layer containing mostly lymphocytes is easily visible. This layer is then removed and further processed by placing the buffy coat in an additional tube and washing the cells washed 3 times 10 in PBS or cell culture media. After each of the wash steps the cells are centrifuged at 400 g for 9 minutes. After the third wash the lymphocytes are collected from the pellet. The cells are counted and diluted to the desired cell concentration. A variety of DMF concentrations were prepared using complete cell culture 15 medium as the diluent. The following concentrations were prepared: 1%, 0.1%, 0.05%, 0.01% and 0.001%. The isolated lymphocytes were diluted to the required concentration using a complete cell culture medium. The complete cell culture medium used in the above steps contained 20 RPMI1640 with HEPES 20-25 mM, L-glutamine 1 mM, dimercapto-ethanol - 19 qlIIRRTITITF RH=I4FT (RULE 261 WO 99/13885 PCT/US98/19126 2x10 5 mM and 10% heat inactivated fetal calf serum. The prepared lymphocytes were placed in 96 well cell culture plates at a concentration of 150,000 cells per well. PHA [Phyto-Heame-Agglutinin] was added to each test well at a concentration of 1 to 10 Itg per 200 AL. At the 5 same time DMF was added to each of the test wells at the predetermined concentration and the culture wells were incubated at 37 0 C in 5% CO 2 , 95% 02 atmosphere for 1 to 4 days. A redox indicator sold under the trademark AlamarBlue was added to each of the culture wells at 10% volume:volume. The cultures were incubated 10 for 18 hours with AlamarBlue prior to determining the absorbance at 570nm with 630nm as a reference. The results may be summarised as follows: The culture in which peripheral lymphocytes from healthy volunteers were exposed to PHA and DMF at 1% concentration for 24 hours reduced 102% 15 of the quantity of AlamarBlue reduced by the culture in the normal PHA growth well. However, for the cultures in which DMF was added at a concentration of only 0.05% reduced only 52% of the quantity of AlamarBlue reduced by the culture containing PHA stimulated lymphocytes. This demonstrates a significant inhibition of metabolic - 20 QIIRWTITIITI= Q.4PPT (RULF 261 WO 99/13885 PCT/US98/19126 activity in the culture well which correlates very closely with the level of cell proliferation in the particular well. When comparing the metabolic activity as indicated by AlamarBlue reduction of unstimulated lymphocytes to unstimulated lymphocytes 5 exposed to low concentration of DMF, a 40% decrease in reduction of AlamarBlue is observed for lymphocytes exposed to 0.05% DMF concentration. [See Figures 1 and 2 which represent typical results of a number of repetitions of the experiment] EXAMPLE 2 10 To demonstrate the postulated mechanism of action of the DMF in causing depression of lymphocyte metabolic activity a further series of experiment was performed. In these experiments the lymphocytes of healthy volunteers were isolated using the technique described in Example 1. After the lymphocytes were isolated the lymphocytes were exposed to DMF at various 15 concentrations for varying lengths of incubation time. The DMF concentrations used were 0.1%, 0.01%, and 0.001% and the incubation times were: 5, 15, 30, 75, 120 and 180 minutes. The Tyrosine kinase activity was determined using a commercially available Tyrosine kinase assay kit available from Boehringer Mannheim [Catalogue Number 1534505]. The 20 results were as presented in the graphs of Figures 3 and 4. Over a 3 hour - 21 S11RQTITI IT= l-I=FT (RULE 261 WO 99/13885 PCT/US98/19126 exposure to a 0.01% concentration of DMF the tyrosine kinase activity of the tested lymphocytes were inhibited by 71%. It is pointed out that in this graph the lower the absorbance reading, the higher the degree of tyrosine kinase activity inhibition. The general shape of the graphs remained the 5 same regardless of the time allowed for development of the colour reaction. The results support the postulate on which the present invention is based that DMF at certain concentrations, when exposed to lymphocytes for a certain period of time serves to block Tyrosine kinase activity. There is the possibility that the observed decreased activity in tyrosine kinases in the 10 tested lymphocytes might be the result of stimulation of certain tyrosine phosphatases. The presented graphs are typical examples of many graphs obtained. EXAMPLE 3 The PTK inhibitory activity of DMF and two of its metabolites was further 15 demonstrated by comparing it to a commercially available PTK inhibitor Piceattanol marketed by Boehringer Mannheim under #1534505 on two cells lines named HELA, a Cervix cancer cell line and HEP3B a liver cancer cell line. The following results were obtained: The inhibitor was used in 10% DMSO solution. - 22 Q1 IRRTITIITF RHI=FT (RULE 261 WO 99/13885 PCT/US98/19126 The test was carried under the following conditions and yielded the results shown below: Slank: 0,043 Funct: Cntrl 5 Endogenous phosphatase: 20.3% Endogenous phosphorylation: 0.14 [0,208] Activity Av. Inhibition HELA Inhibitor : 0,076 [0,132] 10 [Pilleattanol + 10% DMSO] 66% 75% 29,5% Clean Cells 0,115 [0,176] 100% 0% 2% Metabolite I 0,099 [0,167] 86% 95% 9,5% 0,2% Metabolite II 0,074 [0,140] 64% 80% 28,5% 15 2% Metabolite II 0,055 [0,091] 48% 55% 48,5% 0,2% DMF 0,073 [0,146] 63% 83% 27% 2% DMF 0,042 [0,082] 37% 47% 58% HEP3B Inhibitor : 0,055 [0,111] 60% 60% 40% 20 [Pilleattanol + 10% DMSO] 66% 75% 29,5% Clean Cells 0,091 [0,186] 100% 0% 2% Metabolite I 0,090 [0,150] 99% 81% 10% 0,2% Metabolite II 0,036 [0,060] 40% 32% 64% 25 2% Metabolite II 0,095 [0,095] 60% 51% 44,5% 0,2% DMF 0,080 [0,123] 88% 66% 33,3% 2% DMF 0,040 [0,064] 44% 34% 61% IC50 1,7 - 17pM was established IC50 1,7 - 17MM was established 30 CODE Metabolite I - N-methylformamide Metabolite II - N-methylisocyanite DMF - Dimethylformamide -23 RIIRRTITI ITIF .- IFT (RULE 268

Claims

1. A method of affecting an immune response in an animal comprising the steps of administering to such animal a non-toxic, immune modulating effective quantity of a compound selected from the group 5 of compounds consisting of compounds of the general chemical formula (I) R,-CO-NR 2 R 3 (I) wherein R 1 is selected from the group consisting of H and lower [i.e. C 1 10 to C 3 ] alkyl and C 2 to C 3 alkenyl groups; R 2 and R 3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups which may optionally be halogenated or hydroxylated, or which may in combination with one another 15 form a -(CH 2 )n- group wherein n is any number from 2 to 5, or the group -(CH 2 ) 2 -O-(CH 2 ) 2 and metabolites and prodrugs thereof.

2. The method of claim 1 wherein the immune response to be affected by the method is an immune response of the immune cells forming 20 part of the immune system of the body. -24 C IRCTITI ITF CW54FT (R11 F 2RI WO 99/13885 PCT/US98/19126

3. The method of claim 2 wherein the cells are selected from the group consisting of T lymphocytes and B lymphocytes.

4. The method of claim 1 performed to reduce the expression and secretion of immune cell products in the body.

5 5. A method of treatment of an animal afflicted with an ailment associated with inappropriate immune responses in that animal, comprising the steps of administering to such animal a non-toxic therapeutically effective quantity of a compound selected from the group consisting of compounds of the general chemical formula (I) 10 R,-CO-NR 2 R 3 (I) wherein R 1 is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups; R 2 and R 3 are the same or different and each is selected from 15 the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH 2 )n- group wherein n is any number from 2 to 5, or the group -(CH 2 ) 2 -O-(CH 2 ) 2 and metabolites and prodrugs 20 thereof. -25 I IRTITIITF RMFFT (RULE 261 WO 99/13885 PCT/US98/19126

6. The use of a compound selected from the group consisting of compounds of the general chemical formula (I) R , -CO-NR2R 3 (I) wherein 5 R 1 is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups; R, and R3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups which may optionally be halogenated or 10 hydroxylated, or which may in combination with one another form a -(CH 2 )n- group wherein n is any number from 2 to 5, or the group -(CH 2 ) 2 -O-(CH 2 ) 2 and metabolites and prodrugs thereof in the manufacture of a medicament for use in a method of treatment 15 of an animal afflicted with an ailment associated with inappropriate immune responses in that animal.

7. A pharmaceutical composition for use in the treatment of an animal afflicted with an ailment associated with inappropriate immune responses in that animal comprising a compound selected from the 20 group consisting of compounds of the general chemical formula (I) -26 CQ IIR TITIIT= hi :T RI11 F F 9R WO 99/13885 PCT/US98/19126 R 1 -CO-NR 2 R (I) wherein R 1 is selected from the group consisting of H and lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups; 5 R 2 and R3 are the same or different and each is selected from the group consisting of H, lower [i.e. C 1 to C 3 ] alkyl and C 2 to C 3 alkenyl groups which may optionally be halogenated or hydroxylated, or which may in combination with one another form a -(CH 2 ) n - group wherein n is any number from 2 to 5, 10 or the group -(CH 2 ) 2 -O-(CH) 2 and metabolites and prodrugs thereof in a pharmaceutically acceptable dosage form.

8. The method of claim 5, the use of claim 6 or the composition of claim 7 wherein the ailment is selected from the group consisting of: Systemic Lupus Erythematosus [SLE] 15 Scleroderma [Systemic sclerosis] Vasculitis Syndrome [including Wagener's thrombosis and all forms of Giant cell arthritis] Dermatomiositis Asthma 20 Adult Respiratory Distress Syndrome [ARDS] Systemic Inflammatory Response Syndrome [SIRS] -27 C1 IRCTITI IT= I==T IRII 1F 2M WO 99/13885 PCT/US98/19126 Inflammatory Bowel Disease Chronic Hepatitis Rheumatoid Arthritis Rheumatic fever 5 Myasthenia Gravis Multiple Sclerosis Psoriasis Eczema Multiple myeloma 10 Reiter's Syndrome Glomerulonephritis Polymyalgia Rheumatica Ankylosing spondylitis Polyarteritis Nodosa 15 Allergic Rhinitis Diabetes mellitus Optical Neuritis Acute Transversmielitis Head Injuries 20 Spinal Cord injuries Post sub-Arachnoidal Bleeding Vasospasma.

9. The method, use or composition of any one of claims 1 to 8 wherein the compound is dimethylformamide. -28 EIIRRTITIITF RHFFT (RULE 26 WO 99/13885 PCT/US98/19126

10. The method of claim 9 wherein the dimethylformamide is administered to the patient to be treated in a quantity and at a rate sufficient to maintain a DMF-plasma level of between 0.001% and 0.1%. 5

11. The method, use or composition of claim 9 or the method of claim 10 wherein the medicament is, or is adapted to be administered transdermally.

12. The method, use or composition of claim 11 wherein the DMF is administered, or is adapted to be administered by means of a 10 transdermal patch substantially as herein described. -29 -1 IRTITI IT I-41I=T (RIJL 2RI